Relationship between aerobic fitness, the serum IGF-1 profiles of healthy young adult African American males, and growth of prostate cancer cells - Abstract

The growth of prostate tumors is mediated by the bioavailability of androgens and insulin-like growth factors.

This study tested the hypothesis that healthy young adult African American men exhibiting low aerobic capacity (fitness) have serum insulin-like growth Factor-1 (IGF-1) and testosterone levels that promote growth of prostate cancer cells. A cross-sectional data research design was used to study groups of 18- to 26-year-old healthy men exhibiting low and moderate aerobic fitness, based on their peak oxygen consumption (VO2peak). The individual serum levels of IGF-1, IGF-1 binding protein-3 (IGFBP-3), and testosterone were measured. In vitro growth of androgen-dependent LNCaP prostate tumor cells was measured after incubation in culture medium fortified with each subject's serum. Aerobic capacity was significantly greater in the moderate-fitness group than in the low-fitness group without an intergroup difference in body mass index. The serum IGF-1 concentration was significantly higher in the low-fitness group in the absence of an intergroup difference in serum testosterone. The serum IGFBP-3 concentration was significantly lower in the low-fitness group. Prostate tumor cell growth was significantly greater in the cultures incubated in media containing the sera of the low-fitness group than in the sera of the moderate-fitness group. These findings suggest that moderate aerobic fitness in young adults may decrease the circulating levels of free IGF-1 and lower the potential to support growth of prostate cancer cells.

Written by:
Sridhar R, Bond V Jr, Dunmore-Griffith J, Cousins VM, Zhang R, Millis RM.   Are you the author?
Howard University, Washington, DC, USA; The American University of Antigua College of Medicine, St. John's, Antigua & Barbuda.

Reference: Am J Mens Health. 2015 May 19. pii: 1557988315587740.
doi: 10.1177/1557988315587740

PubMed Abstract
PMID: 25990510 Prostate Cancer Section